Detalhe da pesquisa
1.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Nature
; 615(7954): 920-924, 2023 03.
Artigo
Inglês
| MEDLINE | ID: mdl-36922593
2.
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission.
Blood
; 143(5): 417-421, 2024 Feb 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37879077
3.
Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL.
Blood
; 2024 Mar 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38551807
4.
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemia.
Blood
; 142(19): 1647-1657, 2023 11 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37441846
5.
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Blood
; 141(6): 567-578, 2023 02 09.
Artigo
Inglês
| MEDLINE | ID: mdl-36399715
6.
The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.
CA Cancer J Clin
; 68(2): 153-165, 2018 03.
Artigo
Inglês
| MEDLINE | ID: mdl-29338071
7.
Pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, in relapsed or refractory acute myeloid leukaemia: a phase 1/2 study.
Lancet Oncol
; 25(3): 388-399, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38423051
8.
Ivosidenib significantly reduces triazole levels in patients with acute myeloid leukemia and myelodysplastic syndrome.
Cancer
; 2024 Feb 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38340331
9.
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia.
Cancer
; 2024 Apr 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38591430
10.
Phase 1/2 study of CPX-351 for patients with Int-2 or high risk International Prognostic Scoring System myelodysplastic syndromes and chronic myelomonocytic leukaemia after failure to hypomethylating agents.
Br J Haematol
; 204(3): 898-909, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-37946611
11.
Combination therapy with novel agents for acute myeloid leukaemia: Insights into treatment of a heterogenous disease.
Br J Haematol
; 2024 May 09.
Artigo
Inglês
| MEDLINE | ID: mdl-38724457
12.
TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia.
Blood
; 140(1): 58-72, 2022 07 07.
Artigo
Inglês
| MEDLINE | ID: mdl-35390143
13.
The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis.
Blood
; 140(20): 2101-2112, 2022 11 17.
Artigo
Inglês
| MEDLINE | ID: mdl-35877996
14.
Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia.
Blood
; 139(12): 1908-1919, 2022 03 24.
Artigo
Inglês
| MEDLINE | ID: mdl-34914826
15.
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms.
Blood
; 140(16): 1753-1763, 2022 10 20.
Artigo
Inglês
| MEDLINE | ID: mdl-35512188
16.
Outcomes and genetic dynamics of acute myeloid leukemia at first relapse.
Haematologica
; 2024 May 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38695144
17.
Navigating the Management of Chronic Phase CML in the Era of Generic BCR::ABL1 Tyrosine Kinase Inhibitors.
J Natl Compr Canc Netw
; 22(1)2024 02.
Artigo
Inglês
| MEDLINE | ID: mdl-38394773
18.
Ponatinib-review of historical development, current status, and future research.
Am J Hematol
; 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38727135
19.
Targetable genetic abnormalities in patients with acute myeloblastic leukemia across age groups.
Am J Hematol
; 99(4): 792-796, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38361282
20.
Safety and long-term survival results of the addition of inotuzumab ozogamicin to the conditioning regimen of allogeneic stem cell transplantation: A single-center phase 1,2 trial.
Am J Hematol
; 99(5): 836-843, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38400519